In addition to our expansion into surgical devices, we are engaged in research to support patients following ophthalmic surgery. Prof. Francesco Bandello will discuss 'Post-cataract infections: prevention, management and the future' and introduce new data considering the optimal management of post-cataract infectious complications. The discussion will address whether the use of a new topical combination of levofloxacin and dexamethasone followed by dexamethasone alone is not inferior to the standard 2-week tobramycin and dexamethasone treatment in preventing and treating ocular inflammation and in averting infections after cataract surgery.((2))
We are delighted to share these advancements with the community at ESCRS 2019 and look forward to interfacing with the ophthalmology to further address the clinical needs in the ophthalmology community.
References:
1. ESCRS PERSPECTIVE 2. Data on file: LEADER7
About Santen As a specialised company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products and devices. Santen has long been the market leader in Japan for prescription ophthalmic pharmaceuticals and is now a leader in the sector in the EMEA (Europe, Middle East and Africa) region. With scientific knowledge and organisational capabilities nurtured over nearly 130 years, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society in more than 60 countries. For more information, please visit Santen websites www.santen.com (Japan headquarters) and www.santen.eu [http://www.santen.eu/] (EMEA).
About PRESERFLO((TM)) MicroShuntPRESERFLO((TM)) is the new trademark of Innfocus MicroShunt(). PRESERFLO((TM)) MicroShunt will replace Innfocus MicroShunt() in the future.
CONTACT: Garrett Karaaziz, Corporate Communications, Santen EMEA, E:garrett.karaaziz@santen.com, T: +44 (0) 7795 144 9541
Web site: https://www.santen.eu//
